Filter Results:
(124)
Show Results For
- All HBS Web
(380)
- People (2)
- News (124)
- Research (128)
- Events (2)
- Multimedia (6)
- Faculty Publications (72)
Show Results For
- All HBS Web
(380)
- People (2)
- News (124)
- Research (128)
- Events (2)
- Multimedia (6)
- Faculty Publications (72)
Sort by
- 01 Dec 2003
- News
The Next Big Thing
approach to meeting them. This could produce as many as 100,000 high-paying jobs in biotech companies alone, Porter said. Harvard’s Bishop William Lawrence University Professor and an internationally recognized expert on strategy and... View Details
- 01 Dec 2013
- News
Your Own Medicine
searching for new leads. In 2008, Benjy came across an article on halofuginone (HT-100), a drug compound derived from an ancient Chinese herb that had shown promising results in treating muscular dystrophy in mice. They tracked it down to an Israeli View Details
- 22 Feb 2022
- News
An Rx for Small Business Recovery
cluster concept pioneered by Michael Porter, the Bishop William Lawrence University Professor (Renewal Leave) at HBS, Mills argues that organizing a region’s small and large businesses around specialized industries—such as biotech in... View Details
Keywords: Deborah Blagg
- 01 Jun 2007
- News
Mission Possible
“Rudy contends that if we can identify the other ten or twelve genes that are players, we can give the biotech industry so many more shots to come up with a therapy,” explains McCance, who, along with his cofounders, is privately... View Details
- 01 Jun 2003
- News
Student Conferences, at a Glance
Jurvetson; Jeffrey C. Walker (MBA 1981), managing general partner, JPMorgan Partners; Stephen A. Schwarzman (MBA 1972), founding partner, president, & CEO, The Blackstone Group Fewer but better biotech companies are being funded with... View Details
- 01 Oct 2000
- News
The Entrepreneurial Venture
instance, who are the customers, and how do they make decisions? O'Lear: I have been involved in microeconomic (company specific) upheaval. Prior to starting a company with two others, I worked at two high-tech companies: a privately held cardiac ultrasound imaging... View Details
- 05 Aug 2016
- News
Accelerating Change on Medicine’s Final Frontier
program had two origins: Princeton engineering lecturer James Shinn (MBA 1981) and biotech entrepreneur Gregory Stock (MBA 1987), the brother of one of Amadio’s biology professors. “They impressed upon me how interesting it would be to... View Details
Keywords: Robert S. Benchley
- 01 Sep 2014
- News
All For One
don’t know what the answer is. They have to act, not plan their way forward. Hill began to despair of finding an answer to her problem until a chance meeting with Pixar executive Greg Brandeau in the lobby of a biotech firm—Hill was there... View Details
- 01 Jun 2018
- News
Up by the Roots
establishing a platform for building relationships among the relevant actors—to be a replicable model of ecosystem development that could be applied anywhere, and to any industry. (At the moment, she is attempting to strike gold twice in one place by boosting New... View Details
- 01 Dec 2010
- News
This Is What I Do
thus deserve our support.” The MJFF raises about $50 million a year. There are prominent backers, such as Google’s Sergey Brin and his wife, Anne Wojcicki, but nearly 55,000 other people made contributions last year. To date the MJFF has supported about ninety View Details
- 12 Jul 2021
- News
Alumni Confront the COVID-19 Crisis
PYMNTS.com. (Readers who know of groups in need of PPE can email Miller at anne@projectn95.org.) NOVEMBER 23 Cambridge-based biotech Moderna, led by CEO Stephane Bancel (MBA 2000, AMP 170), released promising results on the coronavirus... View Details
- 01 Sep 2009
- News
E Ink’s Wild Ride
that required a massive amount of investment before it could take off,” says Yoffie, who served on E Ink’s board from 1999 to 2004. “The truism is that getting to that point takes longer and costs more money than the most pessimistic forecast. It’s a very similar... View Details